Advertisement
Advertisement
U.S. Markets close in 2 hrs 11 mins
Advertisement
Advertisement
Advertisement
Advertisement

Entheon Biomedical Corp. (1XU1.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.0130-0.0006 (-4.41%)
As of 03:58PM CEST. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close0.0136
Open0.0116
Bid0.0100 x N/A
Ask0.0218 x N/A
Day's Range0.0116 - 0.0130
52 Week Range0.0112 - 0.0380
Volume1,060
Avg. Volume1,256
Market Cap768,160
Beta (5Y Monthly)0.89
PE Ratio (TTM)1.30
EPS (TTM)0.0100
Earnings DateOct 23, 2023 - Oct 27, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 1XU1.F

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Ehave Shareholder from CEO Ben Kaplan and Corporate Update

      MIAMI, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, today issued a letter to shareholders from its Chief Executive Officer, Ben Kaplan. Dear Fellow Shareholders As 2022 draws to a close, many of us will reflect on a year that saw global economic activity experiencing a broad-based and sharper-than-expected slowdown, increased inflation higher than we have seen in seve

    Advertisement
    Advertisement